An Observational Study Using The LumAssure Device In Participants Undergoing Assessment Of Skin Conditions.

NCT ID: NCT06661577

Last Updated: 2024-10-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-13

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study in adult males and females utilising skin condition measurements using the LumAssure Raman device. Data will be used to determine accuracy under the ROC curve (AUCROC) of the LumAssure device for differentiating between benign and cancerous skin conditions. The measurements will provide data which will be used to establish spectral parameters for different skin conditions. Measurements will be benchmarked against diagnoses from medical specialists, and when available confirmed with histological data.

The main question it aims to answer is :

What is the accuracy, in terms of the area under the ROC curve (AUCROC) of the LumAssure device for differentiating between benign skin conditions and skin cancers in adult males and females? Participants include males and females aged ≥18 years who are undergoing assessment of a skin condition (a lesion or rash) by a dermatologist, general practitioner, or plastic surgeon. Participants' attending the clinics will have their skin conditions examined by a clinician. The LumAssure device will then be used to measure Raman spectra of skin conditions and marked by the clinician. The Raman measurements will be benchmarked against skin condition assessment and, where available, diagnosis by a dermatologist, general practitioner, or a plastic surgeon, and for those lesions undergoing biopsy, confirmed with histology data.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For this observational study, Raman spectra will be measured in the clinic using the LumAssure device, on patients attending standard of care medical clinics (SOC participants) for skin assessments and/or biopsies, and on healthy volunteers attending a clinical research centre (HV participants). The LumAssure device was developed and utilised in a previous proof of concept study (https://doi.org/10.1016/j.xjidi.2023.100238). Development of a robust classification algorithm capable of distinguishing between malignant vs benign skin conditions requires the collection of clinical measurements from a large and diverse participant population with varied skin Fitzpatrick types.

Participants will be recruited via advertising. All participants must provide informed consent prior to study participation and data collection. SOC participants lesions of interest will be identified for LumAssure measurement by their medical specialist during their clinical visit.

Participant data will be de-identified, utilizing a unique study number, and entered directly into an electronic data capture system.

The study will be conducted in accordance with the protocol and applicable regulatory requirements. Participant rights and safety, and study data integrity will be monitored by an independent contract research organization in accordance with the protocol and established procedures.

Approximately 1,600 - 3,000 skin conditions assessment data point cases required from an estimated 400-750 participants (with an estimated 1-4 lesions per participant) will be collected for this study. The participant sample size has been determined by an independent biostatistician. The Protocol established criteria for data handling, management and analysis in order to achieve the primary and secondary objectives.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Cancers - Basal Cell Carcinoma Skin Cancers - Squamous Cell Carcinoma Melanoma of Skin Inflammatory Dermatoses Acral Melanoma Benign Skin Nevus Benign Skin Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy volunteers

Male and female healthy volunteers, aged 18 years or over, attending a study specific skin check appointment, without a diagnosis or histology of malignancies.

No interventions assigned to this group

SOC Patients

Participants attending a standard of care medical appointment at a skin clinic, a plastic surgery or a general practitioner for assessment, diagnosis and/or potential excision of a skin condition, With confirmatory medical practitioner diagnosis, and where appropriate confirmatory histological analysis of excised tissues

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to provide informed consent
* Male or female aged 18 years or over.
* Willing to undergo a LumAssure device measurement on at least 1 skin condition
* (For Standard of Care patients): are undergoing a skin examination and/or tissue excision by a qualified specialist
* (For Healthy volunteers): are attending a skin check at a study clinic

Exclusion Criteria

* Tattoo on the skin condition to be measured
* Skin conditions on or directly around the eye area
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Auckland UniServices Ltd.

INDUSTRY

Sponsor Role collaborator

Counties Manukau Health

OTHER

Sponsor Role collaborator

University of Auckland, New Zealand

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michel Nieuwoudt

Senior Research Fellow, Principal Investigator, The School of Chemical Sciences

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michel K Nieuwoudt, PhD

Role: PRINCIPAL_INVESTIGATOR

The University of Auckland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Manukau Super clinic

Auckland, , New Zealand

Site Status

Sir Willliam Manchester Plastic surgery suite, Middlemore Hosptial

Auckland, , New Zealand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

New Zealand

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Michel K Nieuwoudt, PhD

Role: CONTACT

+64210378601

Paul Jarrett, MBBS,DCCH,MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Paul Jarrett, MBBS, DCCH, DGM,MD, FRCP,FRACP

Role: primary

+6421848109

Michelle B Locke, BHB, MBChB, MD,FRACS(Plastics)

Role: primary

+6421963533

Paul Jarrett, MBBS,DCCH,MD,DGM,MD,FRCP,FRACP

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HDEC 21297

Identifier Type: OTHER

Identifier Source: secondary_id

HDEC21297

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Skin Tumor Biomarkers by Mass Spectrometry Imaging
NCT06227416 ACTIVE_NOT_RECRUITING NA